UK drug price deal allows the country to avoid US tariffs by adjusting pricing rules for new medicines.
Author: PharmaSignal News Desk
Belite Stargardt drug shows promising results in a late-stage trial, positioning it for potential regulatory approval.
Protego amyloidosis drug receives $130M funding to develop a new treatment for light chain amyloidosis, aiming to improve patient outcomes.
Novartis job cuts impact Swiss manufacturing, affecting hundreds of employees. Novo’s diabetes drug advances to Phase 3 trials. #Novartis #JobCuts #DiabetesDrug #PharmaSignal
Otsuka secures FDA approval for its first anti-APRIL therapy targeting IgA nephropathy, marking a significant advancement in rare kidney disease treatment.
Contingent value rights are increasingly used in biotech deals to bridge price gaps amid market turbulence.#PharmaSignal #Biotech #MergersAndAcquisitions
UK drug price deal allows the country to avoid US tariffs by adjusting pricing rules for new medicines.
Belite Stargardt drug shows promising results in Phase 3 trial, positioning it for potential market approval.
Protego amyloidosis drug development receives $130M funding to target light chain amyloidosis, potentially improving treatment options.
Novartis job cuts affect hundreds in Swiss manufacturing, while Novo’s diabetes drug advances to Phase 3 trials.